|Table of Contents|

The expression characteristics of T cells in mantle cell lymphoma bone marrow based on CD19/IgM sub-populations

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 08
Page:
1481-1485
Research Field:
Publishing date:

Info

Title:
The expression characteristics of T cells in mantle cell lymphoma bone marrow based on CD19/IgM sub-populations
Author(s):
HU Wenbo; TANG Junling; LI Xiaoming
Department of Hematology,the Affiliated Hospital of Southwest Medical University，Sichuan Luzhou 646000，China．
Keywords:
T cells; sub-populations of CD19/IgM; mantle cell lymphoma
PACS:
R733.4
DOI:
10.3969/j.issn.1672-4992.2023.08.017
Abstract:
Objective:To investigate the differential expression of T cells in bone marrow mononuclear cells of newly diagnosed stage IV mantle cell lymphoma (MCL).Methods:Firstly,the proportions of CD19-/IgM-，CD19-/IgM+，CD19+/IgM-,CD19+/IgM+ sub-populations in healthy donors and MCL group were detected by flow cytometry.Secondly,the total proportion of CD45+CD3+T cells in the two groups was detected.Finally,the ratios of T cells in the four sub-populations of the two groups were detected.Results:There were significant differences among the four sub-populations in each group (P＜0.000 1),and there was no significant difference between the two groups.The percentage of T cells in MCL group (0.46±0.13)% was significantly lower than that in healthy donor group(1.10±0.06)% (P=0.025 1).There was a significant difference in the proportion of T cells among the four sub-populations in the healthy donors group (P＜0.000 1),but such difference wasn' t found in the MCL group (P=0.329 4).The percentage of T cells in the sub-populations of CD19-/IgM- in the MCL group was (0.02±0.01)%,which was lower than that of the healthy donor group (1.51±0.35)% (P＜0.000 1).The percentage of T cells in the sub-population of CD19+/IgM- in healthy donor group and MCL group was (4.28±0.14)% and (0.65±0.45)%,respectively.The ratio of T cells in the sub-population of CD19+/IgM- in MCL group was still significantly decreased (P=0.001 2).There was no statistical difference for the other two subgroups between the two groups.Conclusion:Compared with healthy donors,the total proportion of T cells in bone marrow lesions of newly diagnosed MCL with stage IV was significantly decreased and the percentages of T cells in the sub-populations of CD19-/IgM- and CD19+/IgM-were significantly decreased.It is suggested that the lack of normal number of T cells in the bone marrow lesions of MCL,and leads to weakened immune monitoring,which may promote the occurrence and development of tumors.

References:

［1］ PEREZ-GALAN P,DREYLING M,WIESTNER A.Mantle cell lymphoma:biology,pathogenesis,and the molecular basis of treatmentin the genomic era［J］.Blood,2011,117(1):26-38.
［2］ 陈青,朱璐婷,岑溪南,等.不同病理类型淋巴瘤骨髓侵犯的发生率［J］.中国实验血液学杂志,2018,26(03):765-771. CHEN Q,ZHU LT,CEN XN,et al.Incidence of bone marrow involvement in different pathological type lymphoma patients［J］.Journal of Experimental Hematology，2018,26(03):765－771.
［3］ EYRE TA,CHEAH CY,WANG ML.Therapeutic options for relapsed/refractory mantle cell lymphoma［J］.Blood,2022,139(5):666-677.
［4］ JAIN P,WANG ML.Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis,risk stratification,clinical approach,and current and novel treatments［J］.Am J Hematol,2022,97(5):638-656.
［5］ TANG JL,ZHANG L,ZHOU TJ,et al.Identification and characterization of the cellular subclones that contribute to the pathogenesis of mantle cell lymphoma［J］.Genes Dis,2019,6(4):407-418.
［6］ 钟伟杰,李庆山,李康保,等.人骨髓来源间充质干细胞在肿瘤微环境中上调IL-17A水平激活PI3K/Akt通路促进弥漫大B细胞淋巴瘤生长和化疗耐药［J］.中国肿瘤,2020,29(05):379-390. ZHONG WJ,LI QS,LI KB,et al.Human bone marrow-derived mesenchymal stem cells promote growth and drug-resistance of diffuse large B-cell Lymphoma in tumor microenvironment by up-regulating IL-17A expression via activating PI3K/Akt pathway［J］.China Cancer,2020,29(05):379-390.
［7］ NYGREN L,WASIK AM,BAUMGARTNER-WENNERHOLM S,et al.T-cell levels are prognostic in mantle cell lymphoma［J］.Clin Cancer Res,2014,20(23):6096-6104.
［8］ CHEN Z,AYALA P,WANG M,et al.Prospective isolation of clonogenic mantle cell lymphoma-initiating cells［J］.Stem Cell Res,2010,5(3):212-225.
［9］ MEDINA DJ,ABASS-SHEREEF J,WALTON K,et al.Cobblestone-area forming cells derived from patients with mantle cell lymphoma are enriched for CD133+ tumor-initiating cells［J］.PLoS One,2014,9(4):e91042.
［10］ VALENTIN HS,HOY HM,CEDILE O,et al.Detailed characterization of the transcriptome of single B cells in mantle cell lymphoma suggesting a potential use for SOX4［J］.Sci Rep,2021,11(1):19092.
［11］ KUO PY,JATIANI SS,RAHMAN AH,et al.SOX11 augments BCR signaling to drive MCL-like tumor development［J］.Blood,2018,131(20):2247-2255.
［12］ YANG ZZ,ANNE JN,MARY JS,et al.Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+T cells in B-cell non-Hodgkin lymphoma［J］.Blood,2006,107(9):3639-3646.
［13］ MAHARAJ K,ANGIMAR U,EVA S,et al.Regulatory T cells (Tregs) in lymphoid malignancies and the impact of novel therapies［J］.Front Immunol,2022，13:p.943354.
［14］ ZHANG XY,XU J,ZHU HY,et al.Negative prognostic impact of low absolute CD4(+) T cell counts in peripheral blood in mantle cell lymphoma［J］.Cancer Sci,2016,107(10):1471-1476.
［15］ CHANG BY,FRANCESCO M,DE ROOIJ MF,et al.Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients［J］.Blood,2013,122(14):2412-2424.
［16］ MYKLEBUST JH,IRISH JM,BRODY J,et al.High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells［J］.Blood,2013,121(8):1367-1376.
［17］ ZHANG S,JIANG VC,HAN G,et al.Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma［J］.Nat Commun,2021,12(1):2877.
［18］ CHIRON D,BELLANGER C,PAPIN A,et al.Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma［J］.Blood,2016,128(24):2808-2818.
［19］ SABA NS,LIU D,HERMAN SE,et al.Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma［J］.Blood,2016,128(1):82-92.

Memo

Memo:
泸州市科技局应用基础研究项目（编号：2019LZXNYDJ54）；四川省重点研发项目（编号：2019YFS0301）
Last Update: 1900-01-01